enow.com Web Search

  1. Ads

    related to: list of approved complement inhibitors for diabetes management plan

Search results

  1. Results from the WOW.Com Content Network
  2. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

  3. Eculizumab - Wikipedia

    en.wikipedia.org/wiki/Eculizumab

    Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica.

  4. Empagliflozin/linagliptin/metformin - Wikipedia

    en.wikipedia.org/wiki/Empagliflozin/linagliptin/...

    To reduce the risk of developing ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medications, recommending they be temporarily stopped before scheduled surgery.

  5. Diabetes medication - Wikipedia

    en.wikipedia.org/wiki/Diabetes_medication

    Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.

  6. Zilucoplan - Wikipedia

    en.wikipedia.org/wiki/Zilucoplan

    Zilucoplan is a cyclic peptide that binds to the protein complement component 5 (C5) and inhibits its cleavage into C5a and C5b. [11] Zilucoplan was approved for medical use in the United States in October 2023, [6] [12] in the European Union in December 2023, [7] and in Australia in July 2024. [1]

  7. Empagliflozin - Wikipedia

    en.wikipedia.org/wiki/Empagliflozin

    Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar loss in urine. [2] Empagliflozin was approved for medical use in the United States and in the European Union in 2014. [13] [23] [24] It is on the World Health Organization's List of Essential Medicines. [25]

  1. Ads

    related to: list of approved complement inhibitors for diabetes management plan